Environmental Study of Azole-Resistant Aspergillus fumigatus and Other Aspergilli in Austria, Denmark, and Spain

Antimicrobial Agents and Chemotherapy
2010.0

Abstract

A single mechanism of azole resistance was shown to predominate in clinical and environmental Aspergillus fumigatus isolates from the Netherlands, and a link to the use of azoles in the environment was suggested. To explore the prevalence of azole-resistant A. fumigatus and other aspergilli in the environment in other European countries, we collected samples from the surroundings of hospitals in Copenhagen, Innsbruck, and Madrid, flowerbeds in an amusement park in Copenhagen, and compost bags purchased in Austria, Denmark, and Spain and screened for azole resistance using multidish agars with itraconazole, voriconazole, and posaconazole. EUCAST method E.DEF 9.1 was used to confirm azole resistance. The promoter and entire coding sequence of the cyp51A gene were sequenced to identify azole-resistant A. fumigatus isolates. A. fumigatus was recovered in 144 out of 185 samples (77.8%). Four A. fumigatus isolates from four Danish soil samples displayed elevated azole MICs (8%), and all harbored the same TR/L98H mutation of cyp51A. One A. lentulus isolate with voriconazole MIC of 4 mg/liter was detected in Spain. No azole-resistant aspergilli were detected in compost. Finally, A. terreus was present in seven samples from Austria. Multi-azole-resistant A. fumigatus is present in the environment in Denmark. The resistance mechanism is identical to that of environmental isolates in the Netherlands. No link to commercial compost could be detected. In Spain and Austria, only Aspergillus species with intrinsic resistance to either azoles or amphotericin B were found.

Knowledge Graph

Similar Paper

Environmental Study of Azole-Resistant Aspergillus fumigatus and Other Aspergilli in Austria, Denmark, and Spain
Antimicrobial Agents and Chemotherapy 2010.0
Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus
Antimicrobial Agents and Chemotherapy 2008.0
A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations
Antimicrobial Agents and Chemotherapy 2007.0
Azole Resistance Profile of Amino Acid Changes in Aspergillus fumigatus CYP51A Based on Protein Homology Modeling
Antimicrobial Agents and Chemotherapy 2010.0
In Vitro Activities of Various Antifungal Drugs against Aspergillus terreus : Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility Testing
Antimicrobial Agents and Chemotherapy 2009.0
Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene
Antimicrobial Agents and Chemotherapy 2010.0
Aspergillus Section Fumigati : Antifungal Susceptibility Patterns and Sequence-Based Identification
Antimicrobial Agents and Chemotherapy 2008.0
Avian Aspergillus fumigatus Strains Resistant to both Itraconazole and Voriconazole
Antimicrobial Agents and Chemotherapy 2009.0
Expression, Purification, and Characterization of Aspergillus fumigatus Sterol 14-α Demethylase (CYP51) Isoenzymes A and B
Antimicrobial Agents and Chemotherapy 2010.0
Overexpression of the sterol 14α‐demethylase gene (MgCYP51) in Mycosphaerella graminicola isolates confers a novel azole fungicide sensitivity phenotype
Pest Management Science 2012.0